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Context: Substance use disorders (SUDs) are highly prevalent among inpatient adoles-
cents with psychiatric disorders. In this population, substance use and other psychiatric 
outcomes can reinforce one another. Despite the need for integrated interventions in 
youths with dual diagnoses, few specific instruments are available. App-based tech-
nologies have shown promising results to help reduce substance use in adolescents, 
but their applicability in youths with associated severe psychiatric disorders is poorly 
documented. We aim to evaluate the feasibility of an ecological momentary assessment 
(EMA) intervention for all substance users, and of a smartphone application for cannabis 
users (Stop-Cannabis), for outpatient treatment after hospital discharge.
Methods and analysis: All inpatient adolescents with psychiatric disorders hospitalized 
between 2016 and 2018 in a university hospital will be systematically screened for SUD 
and, if positive, will be assessed by an independent specialist addiction team. Participants 
with confirmed SUDs will be invited and helped to download an EMA app and, if required, 
the Stop-Cannabis app, the week preceding hospital discharge. Information about the 
acceptability and use of both apps and the validity of EMA data in comparison to clinical 
assessments will be assessed after 6 months and 1 year.
discussion: This research has been designed to raise specific issues for consideration 
regarding the sequence between substance use, contextual factors, and other psychiat-
ric symptoms among adolescents with comorbid severe psychiatric disorders. A better 
understanding of the mechanisms involved will inform the development of integrated 
treatment for dual disorders at that age.
Ethics and dissemination: The study has already been approved and granted. 
Dissemination will include presentations at international congresses as well as publica-
tions in peer-reviewed journals.
trial registration: European Clinical Trials Database: Number 2016-001999-30.
Keywords: substance use disorder, cannabis addiction, prevention, adolescents, ecological momentary 
assessment, ecological momentary intervention, mHealth app, smartphone app
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introduCtion
Background
Substance Use Disorders and Psychiatric Disorders 
in Adolescents
Psychiatric comorbidity in adolescents who abuse substances is 
the rule rather than the exception, with 61–88% having a dual 
diagnosis (1, 2). The coexistence of both disorders is associated 
with important disruptions in a range of functional domains, 
including academic attainment, social and family relationships 
(2, 3), and accidents (4). In addition, initiation of substance use 
at a younger age (5) and a faster relapse after treatment (6) are 
reported in youths with preexisting mental health problems. In 
turn, the natural course of psychiatric disorders may be affected 
by substance use, either due to negative psychosocial conse-
quences associated with substance involvement (7) and/or to the 
direct effect of the substance on the central nervous system (8). 
In youths with mood or psychotic disorders, for example, daily 
use of cannabis is associated with a more severe clinical presenta-
tion, impaired cognitive and interpersonal abilities, and poorer 
responses to pharmacological treatments (9). The development 
of integrative treatment for substance use disorders (SUDs) and 
psychiatric disorders is therefore a priority (10, 11).
Among adolescents hospitalized for a psychiatric problem, 
17–50% meet criteria for one or more SUDs (12–17). In a previ-
ous study of adolescents hospitalized in three psychiatric units 
in France, most subjects met criteria for a non-nicotine SUD: 
around 70% for cannabis, 60% for alcohol, and 20% for other sub-
stances (18). Unsurprisingly, those with dual disorders exhibited 
more severe clinical characteristics (e.g., more suicide attempts) 
and a higher level of functional impairment (e.g., more school 
absenteeism) than patients without SUDs. They also received 
more diagnoses of axis 2 comorbidities and were exposed to 
more severe psychological contexts (e.g., maltreatment or loss of 
a first relative) (18). Given the high prevalence of SUDs among 
adolescents who are hospitalized, and the poor clinical outcomes 
due to the negative interplay between both disorders, specific 
preventive interventions for addiction should be developed and 
evaluated in this population.
Addiction Preventive Interventions in Inpatient 
Adolescents with Psychiatric Disorders
It is well established that treatments for SUDs and psychiatric dis-
orders are less effective when provided separately (1, 6). Although 
the efficacy of integrated approaches for the management of dual 
disorders has been demonstrated in adolescents (10, 11), there 
is some concern that – in practice – the so-called “integrated 
approach” often consists of the addition of evidence-based treat-
ments for both problems, with too few specific dual diagnostic 
or therapeutic tools. For example, in order to choose the optimal 
treatment, the sequence between substance use and other psy-
chiatric symptoms in patients’ daily life should be explored, but 
we are not aware of any tool that would measure this pattern. 
Furthermore, treatment compliance is a key prognostic factor 
in addiction. For most teenagers, SUDs are commonly under-
recognized as a health issue (19). The development of tools that 
promote better recognition of patients’ problems with substances, 
and enhance behavior change, would therefore be worthwhile. 
Digital approaches may be a promising avenue for health-related 
interventions among adolescents given their propensity to use 
digital technologies (20–24).
Digital Approaches
The uptake of smartphones in the general population has encour-
aged the development of apps used to facilitate real-time assess-
ment of the patient in his/her natural environment [Ecological 
Momentary Assessment (EMA)] and allowed delivery of smart-
phone app interventions in this context.
Ecological momentary assessment consists of using comput-
ers or other devices to collect self-assessments repeatedly in real-
time, in various situations of the participant’s daily life, either for 
research purposes or to provide participants with timely feedback 
and advice (25). Different terms have been used for this meth-
odology since the 1980s, including “ambulatory assessment,” 
“experience sampling method,” or “real-time data capture.” Even 
though the terms differ, these approaches have the data collection 
in common (e.g., symptoms, behaviors, physiological processes, 
or daily life circumstances) while the participant undergoes 
normal activities. Therefore, this allows the interplay between 
contextual stressors, psychological distress, and maladaptive 
behaviors to be modeled (26). Compared to traditional measures 
using paper–pencil questionnaires, EMA is regarded as having 
many benefits for addiction research, including decreased recall 
bias, decreased contextual bias (25, 27), and increased validity to 
model the temporal sequence of events between risky situations, 
craving, and substance use (28, 29). Although such tools have 
been available for over 30 years, the emergence of smartphone 
applications as a platform for EMA greatly improved the accept-
ability and usability of this technology (30). In the last decade, 
EMA systems have been developed for adolescents with addic-
tions (31) and applied to the assessment of psychiatric symptoms 
in outpatients with internalizing/externalizing disorders (32–36). 
In contrast with adults [e.g., Ref. (37)], EMA has not yet been 
assessed, to our knowledge, for studying the relationship between 
psychiatric symptoms and patterns of substance use in adoles-
cents. In addition, the feasibility of using EMA in adolescents 
with severe psychiatric symptoms remains understudied.
The smartphone app Stop-Cannabis was developed in 2013 
in Geneva, Switzerland with financial support from the local 
Health Department.1 The app aims to help users reduce or stop 
their cannabis use and prevent relapse. Stop-Cannabis consists of 
several modules based on cognitive behavioral therapy strategies, 
motivational interviewing, and relapse prevention programs. 
Particular effort has been made to include the principles of self-
determination (autonomy, competence, and relatedness) (38) into 
the app and promote its customization (39). As in other studies 
(40–42), participant interaction and rewards support the playful 
aspect of the intervention. Personalization of the users’ goals and 
the app main screen may further contribute to increase adoption 
by user (43). The contents of the application are summarized 
below [and described in detail in Ref. (39)]. Since February 2013, 
the Stop-Cannabis app [available on Google Play (Android) and 
1 https://itunes.apple.com/ch/app/stop-cannabis/id532498307?l=fr&mt=8 
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(iOS) App Store] has been downloaded more than 13,000 times, 
and the app is currently used by 1,000 people every month. The 
app was reported to have a good level of acceptability among 
community users in an online satisfaction survey (39).
This study is part of a general collaborative research program 
between the child and adolescent psychiatric department team 
and the addiction unit. The purpose of this wider program is to 
inform the difference in the trajectories of inpatients adolescents 
with SUDs compared to other and to help developing a better 
clinical practice (i.e., early detection, clinical assessment, and 
therapeutics).
objectives
The primary objective of our pilot study is to evaluate the feasibil-
ity and acceptability of two different digital tools (an EMA tool 
and Stop-Cannabis) based on smartphone apps in adolescents 
with dual disorders during a 1-year follow-up period after 
hospital discharge. We aim to determine the feasibility of the 
EMA, adherence to recommendations, and the quality of data 
collected using an EMA digital assessment tool. In addition, 
we aim to evaluate the feasibility, acceptability, and use of the 
Stop-Cannabis app, a digital intervention tool, during outpatient 
aftercare. The authors expect to obtain from this pilot study data 
on the feasibility and acceptability of two kinds of digital tools 
(one related to assessment and the other one to an intervention) 
possibly useful for adolescents with SUDs and comorbid severe 
psychiatric disorders.
Secondary objectives are (1) to estimate the prevalence of 
SUDs in adolescents with psychiatric disorders hospitalized in 
the Department of Child and Adolescent Psychiatry at the Pitié-
Salpêtrière University Hospital, Paris, France (this department 
provides one-third of all child and adolescent inpatient beds 
in the Paris area); (2) to describe the clinical and psychosocial 
characteristics of substance users compared with non-users; 
(3) to determine the risk factors for the onset of SUDs during 
follow-up in participants without dual diagnoses at baseline; 
(4)  to determine the risk factors for the persistence of non-
cannabis SUDs during follow-up; (5) to document the longitu-
dinal interplay between substance use and psychopathology in 
adolescents with dual diagnoses at baseline; and (6) to examine 
the association between the use of the Stop-Cannabis app and 
the patterns of substance use at 1-year follow-up in naturalistic 
settings to inform the potentiality for future research.
MEtHodS and analySiS
Selection of Participants
Inclusion and Exclusion Criteria
Participants will be adolescents (11–18 years old) who are hospi-
talized in the Department of Child and Adolescent Psychiatry at 
the Pitié-Salpêtrière University Hospital between September 2016 
and September 2018. The participants will be assessed at baseline. 
According to the presence or absence of comorbid SUDs, they 
will be included in either the SUDs group or the control group. 
The SUDs group will receive the mobile apps, whereas the control 
group will not. Exclusive tobacco consumption is not considered 
to be a criterion for inclusion in the SUDs group. Inclusion to 
the non-SUD control group will be made according to a match 
with adolescents from the SUDs group (for age, gender, inpatient 
unit, and time of admission). Exclusion criteria include non-
French speaking, those without a personal mobile phone, lack 
of informed consent from parents or from the adolescents, and 
any mental or physical problems that interfere with participation 
in the study (e.g., autism with very low communication abilities, 
severe to profound intellectual disability, severe motor disability).
Sample Size
A conservative approach was adopted for this feasibility 
study, which emphasizes descriptive and qualitative feedback. 
Consequently, based on the recommendations for pilot studies 
(44), we plan to include 80 participants (40 cases, 40 controls) 
over a 2-year inclusion period. As there are around 280 inpatient 
admissions per year in the Department of Child and Adolescent 
Psychiatry, i.e., n = 560 potential participants contacted at base-
line during the 2 years, this will represent a 14% inclusion rate. 
We predict that the prevalence of SUDs will be similar to that 
previously reported (18). A good level of compliance with EMA 
and Stop-Cannabis is expected, consistent with previous studies 
that reported high levels of adherence (up to 80%) to similar 
tools in adolescents with comorbid psychiatric disorders (31, 45), 
and in adults with associated severe psychiatric disorders (32, 
46). An acceptance rate of 80% is expected in the SUD group 
and 50% for the control group. A 50% retention rate at 1-year 
follow-up is anticipated based on previous longitudinal studies 
among adolescents (47). In case of a lower enrollment rate, we 
will either continue to enroll participants during an additional 
year (2019) in order to reach the intended sample size or use 
incentives (e.g., free participation in leisure and sport activities 
in groups) to encourage participant enrollment.
EMa and Stop-Cannabis app tools
Ecological Momentary Assessment
The EMA was designed as an app for mobile phones. This applica-
tion allows several daily self-assessments (e.g., five times a day 
for 2  weeks at different times of the study/monthly). Data are 
collected in response to a signal from the EMA app that occurs 
at various times of the day. The app has been programed to send 
signals (i) a fixed number of times per day at predetermined times 
(e.g., at bedtime) and (ii) at random (with a balance between 
week, weekends, and holidays, with different time intervals in 
daytime). Participants are also asked to complete self-assessment 
immediately following substance use.
The same questions are presented regardless of assessment 
type. There are seven questions in total:
• Information relating to substance use:
 Daily use of each substance in list.
 Level of withdrawal symptoms during participants’ most 
recent period of abstinence from 0 (not at all) to 5 (severe).
 Level of craving from 0 (no urge) to 5 (extreme urge).
• Information relating to psychopathology:
 Level of negative affect rate using a brief version of the 
Positive and Negative momentary Affect Scale (PANAS) (48) 
adapted for EMA (32). Participants provide ratings of 
4Benarous et al. Digital Tools in Dual Disorders
Frontiers in Psychiatry | www.frontiersin.org September 2016 | Volume 7 | Article 157
the extent to which they felt each emotion on a 1–5 point 
Likert-type scale.
 Main psychiatric symptoms.
• Information relating to environment:
 Stressful events.
 Activities: physical activity, planned activity, lone activity, 
social activity with peers, family activity, and online activity.
Participants will be trained on EMA use during the week prior 
to hospital discharge. They will be asked to respond to any signals 
within 1 h if possible. Consistent with other EMA protocols, par-
ticipants will complete 2 days of practice data (not used for analy-
ses), after which they will receive feedback on adequate use and 
compliance. Participants will then be invited to complete EMA 
assessments for 2 weeks, as this timeframe appears sufficient to 
monitor substance use (45). To limit attrition, participants will be 
paid 30€ for completing the baseline assessment and 10€ for each 
week of complete EMA data, up to a maximum possible payment 
of 60€ over 1 year.
The Stop-Cannabis App
Launched in 2013, Stop-Cannabis is available free on iOS and 
Android. It has been continuously updated and improved over the 
past 3 years, in response to users’ suggestions. When people use 
the app for the first time, they are asked to document their objec-
tives and choose a quitting date. The app has several modules. 
First, it allows users to assess their cannabis usage profile (includ-
ing motivations for use and severity of cannabis use) via different 
assessments (49). Users then receive an individually tailored 
feedback message that includes links to online psychoeducation 
and complementary resources. Second, motivational messages 
are regularly delivered using push-notification technology at 
different stages of the quitting process, on the basis of updated 
information regarding current substance use, the selected quit-
ting date, and exposure to situations associated with a high risk of 
relapse documented by high levels of craving or irritability. Third, 
the app includes messages on how to cope with craving symptoms 
or emotional difficulties to enhance participants’ insight into 
contextual factors for substance use. Fourth, positive reinforcers, 
such as the number of days since quitting the substance and the 
amount of money saved, are displayed on the main screen and can 
be personalized (Figure 1). Fifth, a discussion forum called “The 
Tribe,” moderated by a psychologist, is available for all users to 
encourage discussion, mutual support, and information sharing. 
Sixth, the app includes direct access to a website2 for additional 
information about substance use and online motivational inter-
viewing training.
The app will automatically monitor the number of times 
each participant opens the app and records the number of times 
participants looked at or used each element. A Unique Device 
Identifier (UDI) is used to connect the participants’ device to the 
study database and will be replaced in the data set with a random 
ID for anonymity. After study completion, the UDIs will be auto-
matically deleted from users’ devices. The app will be available for 
participants in the intervention group for 12 months. After this 
2 http://www.stop-cannabis.ch 
period, the app will automatically stop data collection. However, 
participants are free to use the app for as long as they want.
design
Screening
The study flowchart is shown in Figure 2. Each patient admitted 
to the Department of Child and Adolescent Psychiatry at the 
Pitié-Salpêtrière University Hospital during the study recruitment 
phase will be systematically screened for SUDs and eligibility at 
admission. The DEP-ADO questionnaire (50) will be used in the 
study to document substance use in the previous 12 months. The 
complete questionnaire is available free online3. The screening 
question will be “During the last twelve months, how often have 
you [has X] used one of the following substances: alcohol, canna-
bis, cocaine, inhalant/solvent, stimulant, hallucinogen, or heroin” 
(examples and trivial names are provided for each substance). 
For each substance, participants and their families will have the 
options of answering: “Never,” “Occasionally,” “Once per month,” 
“Once or twice per week,” “More than three times per week,” or 
“Daily.” The clinician version of the DEP-ADO will be completed 
by the clinician involved in usual care after an interview with 
the adolescent and his/her family. The self-report version will 
be completed by the adolescent, with assistance from a specially 
trained member of the paramedical staff. Assessments will be 
carried out within 3 days following admission and repeated after 
1 week as an inpatient, and again if necessary (especially if the 
clinical condition is not compatible with self-assessment).
Urinary drug tests will be performed on all adolescents hos-
pitalized in the Department of Child and Adolescent Psychiatry 
during the study recruitment phase. The tests screen for the 
presence of cannabis, cocaine, opiates, and amphetamines. In 
the interest of having as broad as possible a representation of the 
target population, we will include as “screen positive” those who 
answer at least “occasionally” to use of cocaine, inhalant/solvent, 
stimulant, hallucinogen, or heroin, and/or at least monthly use 
of cannabis or alcohol, and/or when their urine test indicates the 
presence of one of these substances.
Assessment to Determine Eligibility
All youths screened positively for substance use will be reported to 
the hospital’s liaison addiction unit (ECIMUD, a French acronym 
for coordination and medical care team for addictive disorders) for 
proper diagnosis and care. Systematic evaluation of the substance 
use and habits will be conducted via a semi-structured interview, 
which allows for scoring the RECAP index, the clinician version 
of the DEP-ADO, and the Cannabis Use Screening Test (CAST), 
a self-reported scale that focus on use of cannabis in the previous 
6 months (51). Final diagnoses of SUDs will be made by one of the 
ECIMUD senior psychiatrists using DSM-5 criteria (52).
Initial Clinical Assessment and Follow-Up
Participants (i.e., adolescents with SUDs and control subjects) 
will be approached by a researcher involved in the project (either 
a clinician specialized in child psychiatry or a master’s level 
psychologist) who will explain the study and obtain written 
3 https://oraprdnt.uqtr.uquebec.ca/pls/public/docs/GSC3472/F463443489_DEP_
ADO_ang_V3_2.pdf
FiGurE 1 | Ecological momentary intervention “Stop-Cannabis.” Notes: screenshots of the welcome page, the Feedback page, and the main screen with the 
benefits of change. Adapted from: Monney et al. (39).
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informed consent from parents or guardian and assent from 
the adolescent. Participants will be assessed in the week prior 
to hospital discharge for sociodemographic data, psychosocial 
information, psychopathology, and substance use (see Variables 
and Instruments). All youths will be assessed in face-to-face 
interviews by a specially trained master’s level psychologist at 
6-month and 1-year follow-up.
data analysis
Variables and Instruments
Table 1 lists the questionnaires and other assessments that will 
be used at baseline and at follow-up. The reading level of the 
questionnaires is grade 6. The questionnaires we plan to use 
to measure addiction are described below. A combination of 
self- and clinician-report measures with different time scales 
(i.e., DEP-ADO, 12 months; CAST, 6 months; RECAP, 1 month) 
will be used to examine whether EMA data are consistent with 
information collected in the traditional way. The second type of 
measures relate to psychopathology with the aim of examining 
the interplay between substance use and psychiatric disorders.
Substance Use
• The RECAP index is a clinician-reported questionnaire sys-
tematically used for standardized collection of information 
FiGurE 2 | Flow-chart of the study. Notes: SUD, substance use disorders; DEP-ADO, the questionnaire used for participants’ screening, is detailed in Section 
“Screening”; EMA, ecological momentary assessment; TAU, treatment as usual.
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taBlE 1 | Variables examined in the study.
Variables administration initial assessment Month 6 1 year
Substance use
DEP-ADO Clinician-report self-report X X
RECAP Index Clinician-report X X X
CAST Self-report X X X
ICSU Self-report X X
Misuse of caffeinated sodas Self-report X X
Urinary screening test Biological test X
Psychopathology
K-SADS-PL Semi-structured interview X X
Ado DIB Self-report X X
ARI Parent-report X X X
Self-report
UPPS-P Self-report X X X
C-GAF Self-report X X X
other variables
Age, gender, academic status, socioeconomic status Parent-report X
ACE Self-report X
Satisfaction questionnaire Self-report X X
CSSRI-EU Clinician-report X X X
DEP-ADO, RECAP Index, CAST, Cannabis Use Screening Test; ICSU, Compulsive Internet Use Scale; K-SADS-PL, Kiddie-SADS-Present and Lifetime Version; Ado DIB, Adolescent 
Diagnostic Interview for Borderline Patients; ARI, Affective Reactivity Index; UPPS-P, Impulsive Behavior Scale; C-GAF, Children’s Global Assessment of Functioning; ACE, Adverse 
Childhood Experiences Questionnaire; CSSRI-EU, Client Sociodemographic and Service Receipt Inventory-European Union.
7
Benarous et al. Digital Tools in Dual Disorders
Frontiers in Psychiatry | www.frontiersin.org September 2016 | Volume 7 | Article 157
regarding substance use during the last month in outpatient 
addiction centers in France, recommended by the EMCDDA 
(European Monitoring Centre for Drugs and Drug Addiction) 
(available at http://www.ofdt.fr/enquetes-et-dispositifs/recap/
presentation/).
• The CAST is a 6-item self-reported scale that focuses on the 
use of cannabis in the last 6 months, validated in French (51).
• The Compulsive Internet Use Scale (ICSU) is a 14-item self- 
reported scale that focuses on compulsive internet use (53), 
validated in French (54).
• The pattern of use of caffeinated sodas will be assessed using a 
clinician-reported scale previously used in a French outpatient 
non-clinical sample (55); items are based on Goodman’s crite-
ria for addiction (56).
Psychopathology
• The Kiddie-SADS-Present and Lifetime Version (K-SADS-PL) 
is a semi-structured interview used to assess psychiatric dis-
orders (57).
• The Affective Reactivity Index (ARI) is a 7-item clinician- 
reported scale that focuses on distinct domains of irritability 
(i.e., tonic and phasic), validated in English (58).
• The Impulsive Behavior Scale (UPPS-P) is a 20-item self- 
reported scale that focuses on distinct domains of impulsivity 
(i.e., sensitivity to positive and negative emotions, lack of 
perseverance, lack of premeditation, and sensation-seeking), 
validated in French (59).
• The Adolescent Diagnostic Interview for Borderline Patients 
(Ado DIB) is a self-reported questionnaire that assesses the 
diagnostic criteria for borderline personality disorder. Trans-
lation and validation in French are provided by Guilé and 
colleagues (60).
• Overall functioning will be measured using the Children’s 
Global Assessment of Functioning (C-GAF), one of the most 
widely used measures of the overall severity of adolescent 
disturbance (61).
Other Measures
• Sociodemographic data, including age, gender, academic 
status, and socioeconomic status.
• Adverse life events, collected using the Adverse Childhood 
Experiences Questionnaire (ACE), a 10-item self-reported 
scale that explores the presence of abuse and severe neglect 
during childhood, validated in English (62). Other psycho-
social variables include living arrangements (classified into 
four groups: stable family, unstable family, stable institutional 
care, unstable institutional care), school absenteeism (partial 
or complete), orphan or adopted child, first-degree loss, 
family dysfunction (e.g., parental conflict, parental separation, 
divorce), and educational support.
• The Client Sociodemographic and Service Receipt Inventory-
European Union (CSSRI-EU), a questionnaire completed 
by the clinician that details treatment received (including 
pharmacological treatments) and the type of care (such as the 
number of hospitalizations, outpatient services, emergency 
admission) (63).
• Satisfaction questionnaires for EMA and Stop-Cannabis will 
be completed at 6 months and at end-point (1 year).
Outcomes
Information will be collected from both EMA data and 
from  questionnaires administered during hospitalization and 
follow-up.
Primary Outcomes
The first parameter is whether the level of adherence and 
the acceptability of the EMA and the Stop-Cannabis app are 
satisfactory in this sample. Acceptability will be assessed by 
8Benarous et al. Digital Tools in Dual Disorders
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measuring the dropout rate after 6 and 12 months, and usability 
and satisfaction via questionnaire in all participants and via 
face-to-face interviews with a subgroup of 10 participants. 
Compliance will be assessed via mean percentage of random 
prompts and predetermined assessments completed per partici-
pant. The second parameter is whether information collected 
using EMA via a mobile app is valid and reliable. Information 
obtained by EMA tools using the mobile app will be compared 
to those collected by traditional paper–pencil and clinical 
interview methods during the initial and follow-up assessments 
using correlations analysis.
Secondary Outcomes
(1) The prevalence of SUDs among adolescent inpatients will be 
assessed.
(2) The clinical and psychosocial characteristics of participants 
with and without SUDs at baseline, including history of 
adverse childhood experiences, comorbid psychiatric diagno-
ses, and the level of functional impairment, will be compared.
(3) The risk of developing SUDs among non-SUD adolescents 
during a 1-year follow-up period following hospital dis-
charge will be investigated.
(4) The proportion of inpatient adolescents with non-cannabis 
substance use at baseline whose SUDs persist at 1 year will 
be estimated.
(5) We will explore how psychiatric symptoms could affect the 
pattern of substance use among SUDs participants.
(6) We will assess whether specific patterns of Stop-Cannabis 
app use is associated with substance use outcomes at 1-year 
follow-up.
Statistical Methods
Primary Outcomes
Pearson correlations will be used to determine the strength of 
associations between daily substance use assessed by either EMA, 
or self-report questionnaire (e.g., CAST), or by clinician-report 
questionnaire (e.g., RECAP) during the clinical assessment at 
6  months. Clinical reliability of the EMA will be endorsed if 
the correlations are statistically significantly higher than 0.70. 
Further analyses would be performed to estimate different 
aspects of reliability of the data collected in line with Perrez 
et al. (64). The severity of SUDs at baseline should predict the 
severity of substance use and the level of functional impairment 
at 1 year at least to comparable levels while using EMA data at 
baseline compared with traditional methods. Two simple linear 
regression models will be performed. For both the models, the 
dependent variable will be the severity of SUDs at follow-up; 
in one model, the independent variable will be the severity of 
SUDs based on EMA data (Model A), whereas in the other 
model, the variable will be severity of SUDs based on self- and 
clinician-report (Model B). The estimate of the independent 
variable is expected not to be lower in the Model A than in the 
Model B.
The dropout rate is expected to be less than 40% at 6 months 
and less than 50% at 12 months for both the EMA and traditional 
method, with no significant difference between methods. The 
results of the satisfaction survey will be estimated by analyzing 
the percentage of answers and the differences among the different 
categories using Chi-square analysis.
Secondary Outcomes
(1) The number of inpatients with SUDs will be compared with 
the total number of adolescents admitted to the Department 
during the inclusion period.
(2) Descriptive analyses of clinical and psychosocial variables 
will be conducted. Chi-square will be used to compare 
categorical variables, and Student’s t-test for continuous 
variables. A difference of p < 0.05 will be considered statisti-
cally significant.
(3) Univariate logistic regression analyses will be performed 
to determine whether clinical features (as independent 
variables) predict the onset of SUDs at 1 year (as dependent 
variable) in the non-SUD control group and persistence or 
cessation in the SUD group. Possible mediators of this rela-
tion will be examined using the four-step approach proposed 
by Baron and Kenny (65), followed by a Sobel–Goodman 
test. In particular, we will test the mediation effect of the 
baseline impulsivity score, the baseline level of sensation-
seeking (subscales of the UPPS-P score), and the baseline 
level of mood lability (ARI total score) on the relationship 
between psychopathology and SUDs.
(4) Comparable analyses would be conducted to determine 
the clinical and psychosocial risk factors for the persistence 
of SUDs among those with non-cannabis substance use at 
baseline.
(5) Specific analyses based on mixed-effect models (a random 
effect for participants and fixed effects for time) will be 
performed to examine the interplay between the pattern 
of substance use, psychiatric symptoms, and contextual 
stressors for treating EMA data [as in Ref. (45, 66)]. In 
line with previous recommendations, data will be studied 
at the daily level (with average ratings), at the concurrent 
momentary level, and at the prospective level using both 
linear and non-linear modeling (32). These analyses will 
be performed and presented separately between those 
with cannabis use disorder and the other participants 
to prevent any interference due to the use of the Stop-
Cannabis app.
(6) Correlational analyses will be carried out to examine the 
association between the level of app use (EMA or Stop-
Cannabis) (i.e., mean percentage of random prompts, mean 
percentage of days assessment completed) and participant’s 
clinical outcome at follow-up (i.e., frequency of substance 
use and level of functional impairment at 1 year).
Calendar
March 2016: training the medical team to use the screening tools 
(i.e., DEP-ADO).
December 2016: start of participant inclusion (t0).
December 2017: end of data collection for participants enrolled 
at t0.
November 2018: end of inclusion.
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December 2018 to January 2019: start of analysis of baseline data, 
i.e., prevalence of SUDs.
November 2019: end of data collection for final participants 
included.
December 2019 to January 2020: analysis of final data.
February 2020: preparation of an abstract for submission to 
psychiatric congress.
April 2020: writing one to three articles for psychiatric and addic-
tion journals.
diSCuSSion
anticipated results
Primary Objectives
A degree of correlation higher than 0.70 is expected between 
EMA data and data collected using other methods (particularly 
frequency of use), in line with prior studies (46). EMA should 
lead to predictions regarding the course of SUDs over the 1-year 
follow-up (e.g., in term of persistence, severity, and functional 
impairment) at least as good as other methods; that would be of 
interest for the clinicians involved in usual care. A high level of 
compliance with EMA is expected, despite the relative severity 
of the study sample. Based on previous studies in adolescents 
(45, 67), participants are expected to complete a mean of more 
than 70% of random signals, 50% of end-of-day assessments, and 
40% of both random and end-of-day assessments. Indeed, there 
is good evidence that EMA can be used by patients with severe 
psychiatric disorders (e.g., schizophrenia) or cognitive difficulties 
(32, 46).
Secondary Objectives
This study will measure the prevalence and the characteristics 
associated with the presence of SUDs in a sample of adolescents 
hospitalized in a psychiatric setting. Findings are expected to be 
in a similar range as those previously reported by Daudin et al. 
(18). We will then examine the possible relationship between 
SUDs and specific psychosocial and clinical features of inpatient 
adolescents. We expect this study to confirm that both internal-
ized and externalized disorders are significantly associated with 
SUDs and that the presence of SUDs is associated with a higher 
level of impulsivity, mood dysregulation/borderline traits, and 
sensation-seeking traits (68–70). We predict that a bidirectional 
positive relationship between the level of substance use and 
the severity of other psychiatric symptoms will be noted at a 
daily level, and – if confirmed – that this association would be 
strengthened in a context of interpersonal relationship (with fam-
ily and with peers) compared to other situations. A significant 
negative association between the level of the Stop-Cannabis app 
use and the participant’s clinical outcome at follow-up is expected. 
Such additional exploratory analysis would provide preliminary 
information about the possible benefit of the app in naturalistic 
settings.
limitations
Several limitations may preclude interpretation of our findings. As 
no control group for the Stop-Cannabis app is defined (i.e., sub-
jects with cannabis use disorders without the intervention), the 
effectiveness of the Stop-Cannabis app to reduce or quit cannabis 
cannot be directly examined in our study. Furthermore, one other 
limitation is related to the lack of EMA assessments for the control 
group. The groups cannot be then compared with the EMA data. 
The authors choose to not use EMA assessment for the control 
group in order to avoid possible impact of the assessments on the 
behaviors [for a discussion about the reactivity effect of EMA, 
see Shiffman (25)]. The groups will receive, however at different 
time, a number of clinical assessments useful for the planned 
comparisons. As our study participants will be recruited during 
hospitalization in a university teaching hospital, the sample is 
likely to comprise youths with severe or resistant clinical profiles, 
which could limit the generalizability of our findings. In addition, 
the study design requires that only participants who own a smart-
phone are included, which is a risk for selection bias. Attrition 
biases may result from high dropout rates and low use of the 
app, but incentives and reminder phone calls will be employed to 
improve adherence. However, if important differences in baseline 
characteristics between adherent and non-adherent participants 
are detected, this will be further controlled by regression analyses. 
Finally, no firm conclusion about the benefit of the Stop-Cannabis 
application can be drawn from this study with regards to the lack 
of controlled randomized group.
Clinical and research implications
The utility of app tools for adolescents with dual disorders would 
be of clinical interest, considering the need for evidence-based 
treatments and interventions in this population (71). Longitudinal 
data and mediation analyses would provide preliminary data 
on the mechanisms involved in the relationship between dual 
disorders (Figure 3). A better understanding of this mechanism 
is essential to focus on specific subpopulations in pursuit of 
more integrated treatment and support for their mental health 
and addiction problems. The originality of this study stems from 
the combination of tool-based measures with distinct temporal 
scale: standardized semi-structured interviews at baseline and 
end-point, self-reported non-ecological data obtained every 
6  months, and self-measurement in the individual’s natural 
environment using EMA tools.
Ecological momentary assessment data provide insights 
on the sequence between substance use, contextual factors, 
and psychiatric symptoms that could not have been obtained 
using more traditional self-report measures. This is particularly 
important for adolescents where psychopathology may be more 
fluctuating and context-dependent than in adults. In contrast 
with previous EMA data research projects conducted in chil-
dren and adolescents, our sample encompasses a large range of 
psychiatric disorders with a more severe profile. Finally, in line 
with other studies (72), the insights obtained from EMA may 
not only serve researchers and clinicians but might also benefit 
patients directly as patients become increasingly aware of their 
symptoms.
Finally, this research will provide information that ultimately 
helps determine whether a randomized controlled trial could be 
conducted in the future to test the benefit of a digital interven-
tion based on the Stop-Cannabis app in adolescents with severe 
comorbid psychiatric disorders.
FiGurE 3 | Ecological momentary assessment and other methods to study the relationship between psychopathology and substance use during 
follow-up. Notes: OR, odds ratio; LR, logistic regression; SEM, structural equation modeling; HLM, hierarchical linear modeling; VM, variance modeling. EMA 
collects information regarding substance use, craving sensation, emotional state, coping strategies, nature of stressors, withdrawal symptoms, activity, 
environmental context, and social interaction.
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EtHiCS and diSSEMination
informed Consent and institutional review 
Boards
Regarding patient safety, all participants will receive detailed 
information about local help in case of crisis, emergency, or 
suicidal ideation. Participants will also be informed about, and 
trained how to use, the apps and told what can be expected 
from their use. They will also be advised to consult their doctor 
and share concerns with their family and relatives according 
to their needs. Participants will be instructed to not use the 
apps when it is inconvenient (e.g., in class) or unsafe (e.g., on 
bikes).
Informed consent will be obtained from the adolescent 
and his/her family or legal representatives after they 
have received information about the study objectives and 
procedures. Agreement has already been provided by the 
scientific board of the Institute of Research in Public Health; 
however, data collection will only start when the protocol 
will be approved by the Ethics Committee (EC) of the 
Pitié-Salpêtrière Hospital. In the case of protocol changes, 
an amendment will be submitted to the concerning EC. The 
project has already received financial support from French 
institutions, i.e., la Direction General de la Santé (DGS), 
la Caisse Nationale de l’Assurance Maladie des Travailleurs 
Salariés (CNAMTS), la Mission interministérielle de lutte 
contre les drogues et les conduites addictives (MILDECA), 
and l’Observatoire national des Jeux (ODJ) on the basis of an 
open invitation to tender from the IreSP in 2015 (reference 
“IReSP-15-Prevention-11”).
The study protocol has been recorded on the European Clinical 
Trials Database (EudraCT Number 2016-001999-30).
Confidentiality
In order to ensure patient confidentiality during the study and 
transmission of personal data, a security protocol using a digital 
identification number will be employed.
The collected data will be only accessible to the principal 
investigator and study staff as well as the monitors.
dissemination
After study completion, the results of the primary and secondary 
analyses will be published in international peer-reviewed journals 
(at least one specialized in addiction and another in adolescent 
psychiatry).
If shown to provide valid and reliable information in addition 
to traditional measures, findings would be presented in inter-
national symposiums to consider ways to develop new research 
protocols on dual disorders in adolescents, which involved these 
applications.
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Findings regarding the usefulness and possible benefits of 
the Stop-Cannabis app will be transmitted to the team from the 
University of Geneva who programed the app to suggest possible 
areas for improvement.
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